Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
HeyTea Bets on Coffee, Again
Coffee is a darling among Chinese youth.
Jun 22, 2022 10:25 PM
Can Nayuki Hold Its Ground in the Evermore Competitive On-demand Tea Drinks Industry
Nayuki is one of the largest firms in China’s sprawling on-demand tea drinks industry. Financial indicators such as revenue and operating margins have proved its success in the past. But the ultimate question is, how long can it last?
Jun 07, 2022 11:02 AM